|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Investment in real estate: | ||||||||||||||||||||
| Land and improvements | ||||||||||||||||||||
| Building and improvements | ||||||||||||||||||||
| In-place lease assets | ||||||||||||||||||||
| Above-market lease assets | ||||||||||||||||||||
| Total investment in real estate assets | ||||||||||||||||||||
| Accumulated depreciation and amortization | ||||||||||||||||||||
| Net investment in real estate assets | ||||||||||||||||||||
| Investment in unconsolidated joint ventures | ||||||||||||||||||||
| Total investment in real estate assets, net | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets, net | ||||||||||||||||||||
| Real estate investments and other assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Debt obligations, net | ||||||||||||||||||||
| Below-market lease liabilities, net | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Deferred income | ||||||||||||||||||||
| Liabilities of real estate investments held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Commitments and contingencies (see Note 8) | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Preferred stock, $0.01 par value per share, 10,000 shares authorized, zero shares issued and outstanding at September 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.01 par value per share, 1,000,000 shares authorized, 128,912 and 125,788 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total common stock, $0.01 par value per share, 1,000,000 shares authorized, 128,912 and 125,788 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital (“APIC”) | ||||||||||||||||||||
| Accumulated other comprehensive income (“AOCI”) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Common stock, issued (in shares) | ||||||||||||||||||||
| Common Stock | ||||||||||||||||||||
| Total common stock, issued (in shares) | ||||||||||||||||||||
Loading...
